About CTI BioPharma
CTI BioPharma is a company based in Seattle (United States) founded in 1991 was acquired by Swedish Orphan Biovitrum in May 2023.. The company has 25 employees as of December 31, 2022. CTI BioPharma has completed 1 acquisition, including Zhejiang Novus Pharmaceuticals. CTI BioPharma offers products and services including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines. CTI BioPharma operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seattle, United States
- Employees 25 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cti Biopharma Corp
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$45 M (USD), Post-IPO
Jun 15, 2017
-
Investors
Swedish Orphan Biovitrum
& 2 more
-
Employee Count
25
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Swedish Orphan Biovitrum
(May 10, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CTI BioPharma
CTI BioPharma offers a comprehensive portfolio of products and services, including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medicines for blood-related rare diseases
Innovative therapies for rare immunological conditions
Products for inflammation and genetic diseases
Unlock access to complete
Funding Insights of CTI BioPharma
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $45.0M
-
First Round
First Round
(15 Jan 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Post-IPO - CTI BioPharma | Valuation |
investors |
|
| Dec, 2013 | Amount | Debt – Venture - CTI BioPharma | Valuation |
investors |
|
| Jan, 2011 | Amount | Post-IPO - CTI BioPharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CTI BioPharma
CTI BioPharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Swedish Orphan Biovitrum, Hercules Capital and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CTI BioPharma
CTI BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zhejiang Novus Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Generic drugs, APIs, and dietary supplements are developed and manufactured.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - CTI BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cti Biopharma Comparisons
Competitors of CTI BioPharma
CTI BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cti Biopharma
Frequently Asked Questions about CTI BioPharma
When was CTI BioPharma founded?
CTI BioPharma was founded in 1991 and raised its 1st funding round 19 years after it was founded.
Where is CTI BioPharma located?
CTI BioPharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
How many employees does CTI BioPharma have?
As of Dec 31, 2022, the latest employee count at CTI BioPharma is 25.
What does CTI BioPharma do?
Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).
Who are the top competitors of CTI BioPharma?
CTI BioPharma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does CTI BioPharma offer?
CTI BioPharma offers Haematology Treatments, Immunology Treatments, and Specialty Care Medicines.
How many acquisitions has CTI BioPharma made?
CTI BioPharma has made 1 acquisition, including Zhejiang Novus Pharmaceuticals.
Who are CTI BioPharma's investors?
CTI BioPharma has 3 investors. Key investors include Swedish Orphan Biovitrum, Hercules Capital, and Orbimed.